Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein

Scandinavian Journal of Immunology

Volumn 51, Issue 5, 2000, Pages 497-501

  Lu, Y ^a   Xiao, Y ^a   Ding, J ^a   Dierich, M P ^b   Chen, Ying Hua ^a  

^a Institute of Polymer Science and Engineering   (China)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS ENVELOPE;

AIDS VACCINES; ANIMALS; CATTLE; EPITOPES, B-LYMPHOCYTE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NEUTRALIZATION TESTS; RABBITS;

EID: 0034015622     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00713.x     Document Type: Article

References (22)

1. 1 Connor RI, Korber BTM, Graham BS. Immunological and virological analyses of persons infected by human-immunodeficiency-virus type-1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998;72:1552-76.
2. 2 Moore JP. Back to primary school. Nature 1995;376:115.
3. 3 Moore JP, Burton DR. HIV-1 neutralizing antibodies: how full is the bottle? Nat Med 1999;5:142-4.
4. 4 Chen YH, Xiao Y, Yu TW, Dierich MP. Epitope-vaccine: a new strategy against HIV-1. Immunol Today 1999;20:588-9.
5. 5 Catasti P, Bradbury EM, Gupta G. Structure and polymorphism of HIV-1 third variable loops. J Biol Chem 1995;271:8236-42.
6. 6 Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gp120, V3 domain-specific monoclonal antibody. Nature 1992;355:728-30.
7. 7 Chen YH, Dierich MP. A common epitope on gp41, IFN-α and IFN-β induces protective activity. Immunol Today 1998;19: 586-7.
8. 8 Muster T, Steindl F, Purtscher M. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-7.
9. 9 Purtscher M, Trkola A, Gruber G. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retrov 1994;10:1651-8.
10. 10 Purtscher M, Trkola A, Grassauer A. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 1996;10:587-93.
11. 11 Shafferman A, Jahrling PB, Benveniste RE et al. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci USA 1991;88:7126-30.
12. 12 Lewis MG, Elkins WR, McCutchan FE et al. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 1993;11:1347-55.
13. 13 Chan DC, Fass D, Berger JM. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73.
14. 14 Furuta RA, Wild CT, Weng Y et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998;5:276-9.
15. 15 Lacasse RA, Follis KE, Trahey M. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 1999; 283:357-62.
16. 16 Chong P, Chan N, Kandil A et al. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines. Infect Immun 1997;65:4918-25.
17. 17 Siber GR, Anderson R, Habafy M, Gupta RK. Development of a guinea-pig model to assess immunogenicity of Haemophilus influenzae type-B capsular polysaccharide conjugate vaccines. Vaccine 1995;13:525-31.
18. 18 Chen YH, Yu TW, Bai Y, Dierich MP. Immunogenicity of the GPGRAFY-epitope on synthetic peptides. Immunol Lett, in press.
19. 19 Igarashi T, Xxxxxxx XX, Xxxxxxx XX et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 1999;5:211-6.
20. 20 Geffin RB, Scott GB, Melenwick M et al. Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1. AIDS Res Hum Retroviruses 1998;14:579-90.
21. 21 Mascola JR, Louder MK, Vancott TC et al. Potent and synergistic neutralization of human immunodeficiency-virus (HIV) type-1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal-antibodies 2F5 and 2G12. J Virol 1997;71:7198-206.
22. 22 Montefiori DC, Xxxxxxx XX, Xxxxxxx XX et al. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency type 1. J Virol 1998;72: 3427-31.